The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration

Molecular Cancer Research

Volumn 10, Issue 3, 2012, Pages 415-427

  Chiu, Chiang Yen ^a   Kuo, Kung Kai ^b   Kuo, Tzu Lei ^a   Lee, King The ^b   Cheng, Kuang Hung ^a  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; CYCLIN B1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INCIDENCE; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE INDUCTION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; CARCINOMA, HEPATOCELLULAR; CDC2 PROTEIN KINASE; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN B1; DOWN-REGULATION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; SMAD4 PROTEIN; UP-REGULATION;

EID: 84863365843     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0293     Document Type: Article

References (50)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17. (Pubitemid 37518510)
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Kudo M, Han KH, Kokudo N, Cheng AL, Choi BI, Furuse J, et al. Liver Cancer Working Group Report. Jpn J Clin Oncol 2010;40:i19-27
4. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1-10.
5. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nature 2006;6:674-87. (Pubitemid 44286000)
6. Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, et al. Liver stem cells and hepatocellular carcinoma. Hepatology 2009;49: 318-29.
7. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48:S20-37.
8. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
9. Lemaigre FP. Mechanisms of liver development: concepts for understanding liver disorders and design of novel therapies.Gastroenterology 2009;137:62-79.
10. van Wijk B, Moorman AF, van den Hoff MJ. Role of bone morphogenetic proteins in cardiac differentiation. Cardiovasc Res 2007;74: 244-55. (Pubitemid 46517505)
11. Murali D, Yoshikawa S, Corrigan RR, Plas DJ, Crair MC, Oliver G, et al. Distinct developmental programs require different levels of Bmp signaling during mouse retinal development. Development 2005;132: 913-23. (Pubitemid 40484926)
12. Rossi JM, Dunn NR, Hogan BL, Zaret KS. Distinct mesodermal signals, including BMPs from the septum transversum mesenchyme, are required in combination for hepatogenesis from the endoderm. Genes Dev 2001;15:1998-2009. (Pubitemid 32738628)
13. Zaret KS, Grompe M. Generation and regeneration of cells of the liver and pancreas. Science 2008;322:1490-4.
14. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem 2009;147:35-51.
15. Nohe A, Keating E, Knaus P, Petersen NO. Signal transduction of bone morphogenetic protein receptors. Cell Signal 2004;16:291-9. (Pubitemid 37542404)
16. Cheng KH, Ponte JF, Thiagalingam S. Elucidation of epigenetic inactivation of SMAD8 in cancer using targeted expressed gene display. Cancer Res 2005;64:1639-46 (Pubitemid 38428684)
17. Thawani JP, Wang AC, Than KD, Lin CY, La Marca F, Park P. Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery 2010;66:233-46.
18. Langenfeld EM, Kong Y, Langenfeld J. Bone morphogenetic protein-2-induced transformation involves the activation of mammalian target of rapamycin. Mol Cancer Res 2005;3:679-84. (Pubitemid 43042997)
19. Alarmo EL, Kuukasj€arvi T, Karhu R, Kallioniemi A. A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Res Treat 2007;103:239-46.
20. Ketolainen JM, Alarmo EL, Tuominen VJ, Kallioniemi A. Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4. Breast Cancer Res Treat 2010;124:377-86.
21. Rothhammer T, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 2005;65: 448-58.
22. Herrera B, van Dinther M, Ten Dijke P, Inman GJ. Autocrine bone morphogenetic protein-9 signals via activin receptor like kinase-2/ Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res 2009;69:9254-62.
23. Maegdefrau U, Amann T, Winklmeier A, Braig S, Schubert T, Weiss TS, et al. Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. J Pathol 2009;218:520-9.
24. Pan H, Califano J, Ponte JF, Russo AL, Cheng KH, Thiagalingam A, et al. Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smokeinduced non-small cell lung cancer. Cancer Res 2005;65:1664-9. (Pubitemid 40478590)
25. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006; 20:3130-46. (Pubitemid 44790628)
26. Papageorgis P, Cheng K, Ozturk S, Gong Y, Lambert AW, Abdolmaleky HM. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res 2011;71:1-11.
27. Hamada S, Satoh K, Hirota M, Kimura K, Kanno A, Masamune A, et al. Bone morphogenetic protein 4 induces epithelial-mesenchymal transition through MSX2 induction on pancreatic cancer cell line. J Cell Physiol 2007;213:768-74. (Pubitemid 350058270)
28. Piccirillo SG, Vescovi AL. Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst Schering Found Symp Proc 2006;5:59-81
29. Bunyaratavej P, Hullinger TG, Somerman MJ. Bone morphogenetic proteins secreted by breast cancer cells upregulate bone sialoprotein expression in preosteoblast cells. Exp Cell Res 2000;260: 324-33.
30. Shepherd TG, Thériault BL, Nachtigal MW. Autocrine BMP4 signalling regulates ID3 proto-oncogene expression in human ovarian cancer cells. Gene 2008;414:95-10.
31. Mishina Y, Suzuki A, Ueno N, Behringer RR. Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes Dev 1995;9:3027-37. (Pubitemid 26018138)
32. Mishina Y, Hanks MC, Miura S, Tallquist MD, Behringer RR. Generation of Bmpr/Alk3 Conditional Knockout mice. Genesis 2002;32:69-72. (Pubitemid 34211699)
33. Zhou XP, Woodford-Richens K, Lehtonen R, Kurose K, Aldred M, Hampel H, et al. Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan- Riley-Ruvalcaba syndromes. Am J Hum Genet 2001;69:704-11. (Pubitemid 32868516)
34. Baur ST, Mai JJ, Dymecki SM. Combinatorial signaling through BMP receptor IB and GDF5: shaping of the distal mouse limb and the genetics of distal limb diversity. Development 2000;127:605-19. (Pubitemid 30093408)
35. Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH, et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein developmental pathway inhibits differentiation of human glioblastoma tumor initiating cells. Cancer Cell 2008;13:69-80. (Pubitemid 350309742)
36. Bokobza SM, Ye L, Kynaston HE, Mansel RE, Jiang WG. Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. Cancer Genomics Proteomics 2009;6:101-8.
37. Lindqvist A, van Zon W, Karlsson Rosenthal C, Wolthuis RM. Cyclin B1-Cdk1 activation continues after centrosome separation to control mitotic progression. PLoS Biol 2007;5:1127-37. (Pubitemid 46790402)
38. Van Horn RD, Chu S, Fan L, Yin T, Du J, Beckmann R, et al. Cdk1 activity is required for mitotic activation of aurora a during G2/M transition of human cells. J Biol Chem 2010;285:21849-57.
39. Wolf F, Wandke C, Isenberg N, Geley S. Dose-dependent effects of stable cyclin B1 on progression through mitosis in human cells. EMBO J 2006;25:2802-13. (Pubitemid 43980387)
40. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997;106:348-60. (Pubitemid 27510848)
41. Frémin C, Bessard A, Ezan F, Gailhouste L, Régeard M, Le Seyec J, et al. Multiple division cycles and long-term survival of hepatocytes are distinctly regulated by extracellular signal-regulated kinases ERK1 and ERK2. Hepatology 2009;49:930-9.
42. Greulich H, Erikson RL. An analysis of Mek1 signaling in cell proliferation and transformation.J Biol Chem 1998;273:13280-8. (Pubitemid 28246901)
43. Lukas C, Sørensen CS, Kramer E, Santoni-Rugiu E, Lindeneg C, Peters JM, et al. Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 1999;401:815-8.
44. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, et al. E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. Genes Dev 2002;16:245-56. (Pubitemid 34075816)
45. Korotayev K, Chaussepied M, Ginsberg D. ERK activation is regulated by E2F1 and is essential for E2F1-induced S phase entry. Cell Signal 2008;20:1221-6.
46. Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M, et al. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 2001;21: 4684-99 (Pubitemid 32588250)
47. Black EP, Hallstrom T, Dressman HK, West M, Nevins JR. Distinctions in the specificity of E2F function revealed by gene expression signatures. Proc Natl Acad Sci U S A 2005;102:15948-53. (Pubitemid 41552848)
48. Yue J, Frey RS, Mulder KM. Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGFbeta. Oncogene 1999;18:2033-7. (Pubitemid 29150091)
49. Zhou Q, Heinke J, Vargas A, Winnik S, Krauss T, Bode C, et al. ERK signaling is a central regulator for BMP-4 dependent capillary sprouting. Cardiovasc Res 2007;76:390-9. (Pubitemid 350007461)
50. Deng H, Ravikumar TS, Yang WL. Overexpression of bone morphogenetic protein 4 enhances the invasiveness of Smad4-deficient human colorectal cancer cells. Cancer Lett 2009;281:220-31.